| Literature DB >> 27729770 |
Bincy Baby1, Priya Antony1, Walaa Al Halabi1, Zahrah Al Homedi1, Ranjit Vijayan1.
Abstract
Polypharmacology, the discovery or design of drug molecules that can simultaneously interact with multiple targets, is gaining interest in contemporary drug discovery. Serine/threonine kinases are attractive targets for therapeutic intervention in oncology due to their role in cellular phosphorylation and altered expression in cancer. Quercetin, a naturally occurring flavonoid, inhibits multiple cancer cell lines and is used as an anticancer drug in Phase I clinical trial. Quercetin glycosides have also received some attention due to their high bioavailability and activity against various diseases including cancer. However, these have been studied to a lesser extent. In this study, the structural basis of the multitarget inhibitory activity of quercetin and isoquercitrin, a glycoside derivative, on serine/threonine kinases using molecular modeling was explored. Structural analysis showed that both quercetin and isoquercitrin exhibited good binding energies and interacted with aspartate in the highly conserved Asp-Phe-Gly motif. The results indicate that isoquercitrin could be a more potent inhibitor of several members of the serine/threonine kinase family. In summary, the current structural evaluation highlights the multitarget inhibitory property of quercetin and its potential to be a chemical platform for oncological polypharmacology.Entities:
Keywords: docking; isoquercitrin; polypharmacology; quercetin; serine/threonine kinases
Mesh:
Substances:
Year: 2016 PMID: 27729770 PMCID: PMC5045902 DOI: 10.2147/DDDT.S118423
Source DB: PubMed Journal: Drug Des Devel Ther ISSN: 1177-8881 Impact factor: 4.162
Figure 1Structure of (A) quercetin and (B) isoquercitrin.
Figure 2Structure of serine/threonine kinases.
Notes: The protein is shown in cartoon representation and colored in rainbow colors with violet at the N-terminus and red at the C-terminus of the structure. The N- and C-lobes with the connecting hinge region are indicated. The catalytic loop, activation loop, glycine-rich loop, C-helix, and the DFG motif are labeled. The Chk1 protein structure (PDB ID: 1ZYS) belonging to the CaMK family of serine/threonine protein kinases was used to generate this image.
Abbreviations: C-lobe, C-terminal lobe; DFG, Asp–Phe–Gly; N-lobe, N-terminal lobe; PDB, Protein Data Bank.
Proteins and PDB IDs of structures used in this study
| Groups | Protein | PDB ID | Resolution (Å) |
|---|---|---|---|
| AGC | Akt1 | 3MVH | 2.01 |
| Akt2 | 2UW9 | 2.10 | |
| Aurora kinase | 4J8M | 1.85 | |
| RSK2 | 4NW5 | 1.94 | |
| CaMK | Chk1 | 1ZYS | 1.70 |
| CMGC | CDK2 | 4EK4 | 1.55 |
| ERK2 | 4ZZN | 1.33 | |
| p38α | 4R3C | 2.06 | |
| JNK1 | 4QTD | 1.50 | |
| GSK3B | 1J1B | 1.80 | |
| CLK1 | 1Z57 | 1.70 | |
| STE | MEK1 | 3VVH | 2.00 |
| PAK4 | 2Q0N | 1.75 | |
| Plk1 | 2RKU | 1.95 | |
| TKL | B-Raf | 5CSW | 2.66 |
Abbreviation: PDB, Protein Data Bank.
Interactions of quercetin, isoquercitrin, and selected inhibitors with serine/threonine kinases
| Group | Target | PDB ID | Ligand | Hydrogen bonds | Hydrophobic interactions | π–π or cation–π interactions | XP GlideScore (kcal/mol) | MM–GBSA binding energy (kcal/mol) |
|---|---|---|---|---|---|---|---|---|
| AGC | Akt1 | 3MVH | Quercetin | Glu228, Ala230, Asp292 | Leu156, Val164, Ala177, Met227, Tyr229, Met281, Phe438, Phe442 | −9.79 | −64.71 | |
| Isoquercitrin | Glu228, Asp292 | Leu156, Val164, Ala177, Met227, Tyr229, Ala230, Met281, Phe438, Phe442 | −9.86 | −69.79 | ||||
| GSK690693 | Asp439 | Leu156, Phe161, Val164, Ala177, Leu181, Phe236, Phe237, Met281, Tyr437, Phe438 | Phe442 | −5.42 | −64.09 | |||
| Akt2 | 2UW9 | Quercetin | Lys160, Glu230, Ala232, Thr292, Asp293 | Leu158, Val166, Ala179, Met229, Tyr231, Met282, Phe439, Phe443 | −9.97 | −63.45 | ||
| Isoquercitrin | Lys160, Glu236, Lys277, Asp293, Asp440 | Leu158, Val166, Ala179, Met229, Phe238, Phe239, Met282, Phe439, Phe443 | −10.91 | −68.70 | ||||
| GSK690693 | Leu158, Thr213, Asn280, Asp440 | Val166, Ala179, Met229, Tyr231, Ala232, Phe239, Met282, Tyr438, Phe439, Phe443 | −7.10 | −73.94 | ||||
| Aurora | 4J8M | Quercetin | Leu139, Glu211, Ala213, Asp274 | Val147, Ala160, Leu194, Leu210, Tyr212, Leu263, Ala273 | −8.16 | −62.39 | ||
| Isoquercitrin | Glu211, Ala213, Asp274 | Leu139, Val147, Ala160, Leu194, Leu210, Tyr212, Leu263, Ala273, Ala281, Pro282 | −10.22 | −71.01 | ||||
| AT9283 | Ala213, Thr217 | Leu139, Val147, Ala160, Leu194, Leu210, Tyr212, Pro214, Tyr219, Leu263, Ala273, Ala281 | −6.71 | −70.34 | ||||
| RSK2 | 4NW5 | Quercetin | Leu74, Leu150, Asp211 | Val82, Leu147, Ala98, Phe149, Leu200 | −10.14 | −69.17 | ||
| Isoquercitrin | Gln76, Asp148, Leu150, Asn198 | Leu74, Val82, Ala98, Phe149, Leu200, Val131, Leu147 | −12.44 | −88.84 | ||||
| BI-D1870 | Lys72, Leu150 | Leu74, Val82, Ala98, Leu200, Val131, Leu147, Phe149 | −8.41 | −78.42 | ||||
| CaMK | Chk1 | 1ZYS | Quercetin | Lys38, Glu85, Cys87, Asp148 | Leu15, Tyr20, Val23, Ala36, Val68, Leu84, Tyr86, Leu137 | −8.38 | −63.43 | |
| Isoquercitrin | Glu17, Cys87, Asn135, Asp148 | Leu15, Tyr20, Val23, Ala36, Val68, Leu84, Tyr86, Leu137, Phe149 | −11.67 | −79.53 | ||||
| AZD7762 | Glu85, Cys87, Glu91 | Leu15, Tyr20, Val23, Ala36, Leu84, Val68, Tyr86, Leu137 | −7.15 | −83.52 | ||||
| CMGC | CDK2 | 4EK4 | Quercetin | Leu83, Gln131, Asp145 | Ile10, Val18, Ala31, Phe82, Leu134, Ala144 | −9.33 | −64.14 | |
| Isoquercitrin | Thr14, Lys33, Leu83, Gln131, Asp145 | Ile10, Val18, Ala31, Leu134 | −10.49 | −70.09 | ||||
| Dinaciclib | Lys33, Asp86, Lys89 | Ile10, Val18, Ala31, Val64, Phe80, Phe82, Leu83, Leu134, Ala144 | −5.57 | −75.63 | ||||
| ERK2 | 4ZZN | Quercetin | Lys52, Met106, Asp109, Asp165 | Ile29, Ala33, Tyr34, Val37, Ala50, Ile82, Leu105, Leu154, Cys164 | −6.69 | −59.57 | ||
| Isoquercitrin | Gln103, Met106, Asp109, Asp165 | Ile29, Ala33, Tyr34, Val37, Ala50, Ile82, Leu105, Leu154, Lys164 | Lys52 | −8.61 | −68.49 | |||
| SCH772984 | Lys52, Asp104, Lys112 | Ile29, Ala33, Val37, Ala50, Ile82, Leu105, Tyr111, Met106, Leu154, Lys164 | −6.61 | −74.69 | ||||
| p38α | 4R3C | Quercetin | Lys53, Met109, Asp112, Asp168 | Val30, Val38, Ala51, Ile84, Leu108, Ala111, Leu167, Met179, Tyr182 | −6.69 | −44.85 | ||
| Isoquercitrin | His107, Met109, Asp112, Asp168 | Val30, Val38, Ala51, Ile84, Leu108, Leu167, Met179, Tyr182 | −9.31 | −69.86 | ||||
| Doramapimod | Asp168 | Val30, Ala34, Tyr35, Val38, Ala51, Leu75, Ile84, Leu108, Met109, Ala111, Ala157, Leu167, Phe169 | −4.87 | −79.74 | ||||
| JNK1 | 4QTD | Quercetin | Ala36, Lys55, Glu73, Asp151, Asn156, Leu168 | Val40, Ile86, Met108, Leu172, Val187 | −8.20 | −45.53 | ||
| Isoquercitrin | Ala36, Arg69, Asp151, Ser155, Asn156, Leu168 | Val40, Ile86, Met108, Phe170, Leu172, Val186, Val187 | Arg69 | −10.60 | −50.23 | |||
| AS601245 | Lys55, Met111 | Ile32, Ala36, Val40, Ala53, Ile86, Met108, Leu110, Val158, Leu168 | −9.03 | −81.19 | ||||
| GSK3B | 1J1B | Quercetin | Lys85, Val135, Gln185, Asp200 | Ile62, Val70, Ala83, Val110, Leu132, Tyr134, Leu188, Cys199 | −9.29 | −55.35 | ||
| Isoquercitrin | Ile62, Asn64, Lys85, Val135, Arg141, Gln185, Asp200 | Val70, Val110, Leu132, Tyr134, Pro136, Tyr140, Leu188, Cys199, Phe201 | Arg141 | −10.44 | −62.59 | |||
| CHIR-99021 | Ile62, Asn64 | Val70, Ala83, Leu108, Val110, Leu132, Tyr134, Val135, Pro136, Leu188, Cys199 | Lys85, Arg141 | −5.94 | −67.09 | |||
| CLK1 | 1Z57 | Quercetin | Leu167, Lys191, Asp250, Asp325 | Phe172, Val175, Ala189, Val225, Phe241, Leu243, Leu244, Leu295, Val324 | −8.99 | −62.96 | ||
| Isoquercitrin | Gly245, Asp250, Asp325 | Leu167, Phe172, Val175, Ala189, Val225, Phe241, Leu243, Leu244, Leu246, Tyr249 Leu295, Val324 | −10.53 | −73.19 | ||||
| STE | MEK1 | 3VVH | Quercetin | Leu74, Glu144, Met146, Asn195, Asp208 | Ala76, Val82, Ala95, Val127, Met143, Leu197, Cys207 | −9.97 | −64.99 | |
| Isoquercitrin | Met146, Ser194, Asp152, Asp208 | Leu74, Ala76, Val82, Ala95, Met143, Leu197, Cys207 | −9.65 | −68.12 | ||||
| PAK4 | 2Q0N | Quercetin | Glu329, Glu396, Leu398, Asp458 | Ile327, Val335, Ala348, Val379, Met395, Phe397, Leu447 | −10.03 | −58.22 | ||
| Isoquercitrin | Glu396, Leu398, Ala402, Asp458 | Ile327, Val335, Ala348, Val379, Met395, Phe397, Leu447 | −9.86 | −60.47 | ||||
| Plk1 | 2RKU | Quercetin | Leu59, Lys82, Glu131, Cys133, Asp194 | Cys67, Ala80, Val114, Leu130, Leu132, Phe183, Phe195 | −10.89 | −62.84 | ||
| Isoquercitrin | Leu59, Lys82, Glu140, Cys133, Asp194 | Cys67, Ala80, Val114, Leu130, Leu132, Leu139 | Phe183 | −11.26 | −74.86 | |||
| TKL | B-Raf | 5CSW | Quercetin | Cys532, Asp594, Phe595 | Ile463, Phe468, Val471, Ala481, Leu505, Leu514, Ile527, Trp531, Phe583 | −9.48 | −60.46 | |
| Isoquercitrin | Cys532, Gly534, Ser536, Asn580, Phe583, Asp594 | Leu514, Ile463, Val471, Ala481, Trp531, Tyr538 | −11.07 | −67.72 |
Abbreviations: MM–GBSA, molecular mechanics–generalized Born surface area; PDB, Protein Data Bank; XP, extra precision.
Figure 3Docked pose and hydrogen bond interactions of quercetin and isoquercitrin with serine/threonine protein kinases.
Notes: One protein has been chosen from each group. (A) Quercetin in Akt1 (AGC group), (B) isoquercitrin in Akt1, (C) quercetin in Chk1 (CaMK group), (D) isoquercitrin in Chk1, (E) quercetin in CDK2 (CMGC group), (F) isoquercitrin in CDK2, (G) quercetin in MEK1 (STE group), (H) isoquercitrin in MEK1, (I) quercetin in B-Raf (TKL group), (J) isoquercitrin in B-Raf. The protein is shown in light-blue cartoon representation, interacting residues are shown in stick representation, and the docked ligand is represented as black sticks.
Abbreviation: PDB, Protein Data Bank.